Eli Lilly and Company
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date 2024 2023 2022 2021
Total reported revenue 41.0T 34.1B 28.5B 28.3B
Cost of revenue 7.7T 7.1B 6.6B 7.3B
Gross profit 33.3T 27.0B 21.9B 21.0B
Operating expense
Research & development 10.0T 9.3B 7.2B 6.9B
Selling general and admin 7.4T 6.9B 6.1B 6.1B
Other operating expenses
Operating income 15.9T 10.8B 8.7B 7.9B
Non operating interest income
Income 159.5B 173.6M 62.8M 25.4M
Expense 710.8B 485.9M 331.6M 339.8M
Other income expense -3.8T -3.9B -1.6B -1.5B
Pretax income 11.5T 6.6B 6.8B 6.2B
Tax provision 1.9T 1.3B 561.6M 573.8M
Net income 9.6T 5.2B 6.2B 5.6B
Basic EPS 11.8 5.8 6.6 5.9
Diluted EPS 11.7 5.8 6.6 5.9
Basic average shares 817.2B 945.7K 999.1K 1.0M
Diluted average shares 817.2B 945.7K 999.1K 1.0M
EBITDA 17.7T 12.5B 10.2B 9.6B
Net income from continuing op. 9.6T 5.2B 6.2B 5.6B
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed (non-working day)
Main market opens in 12 hours 53 minutes

20:36
00:00
23:59

Trading Hours (Monday - Friday):

Main market
09:30 - 16:00
All times are displayed in the America/Santiago timezone (-03, UTC-03:00).